The Structural Genomics Consortium has generated a set of more traditional small molecule inhibitors of the Win site [92,93,94,95,96,97], one of which, OICR-9429 (Kd ~ 100 nM), inhibits MLL1-HMT activity in vitro and shows inhibition of cancer cell lines in culture. Here, KMT2A is linked to cancer.